XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders Equity (Tables)
 9 Months Ended
Sep. 30, 2023
Stockholders Equity [Abstract]  
Schedule of Outstanding Warrants to Purchase Common Stock Issued To Stockholders As of September 30, 2023, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders:
Warrant  Issuance Date  Expiration Date  Exercise
Price Per
Share		   Number of
Shares of
Common
Stock
Underlying
Warrants		 
Private Placement Warrants  IPO (December 13, 2018)  December 13, 2023   11.50    2,900,000 
Public Warrants  IPO (December 13, 2018)  October 28, 2024   11.50    3,500,000 
2021 Registered Direct Offering Warrants  SPA (July 28, 2021)  January 28, 2027   5.00    2,812,501 
Pre-Funded Warrants  February 27, 2023  -   0.001    2,776,428 
Pre-Funded Warrants  May 4, 2023  -   0.001    11,834,286 
               23,823,215 
Schedule of Black-Scholes Option-Pricing Model The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions:
   Nine Months Ended
September 30,		 
   2023   2022 
Underlying value of Common Stock ($)   0.36-0.40    0.37-1.41 
Exercise price ($)   0.36-0.40    0.37-1.41 
Expected volatility (%)   94.3-96.6    85.3-88.4 
Expected terms of the option (years)   6.11    5.31-6.11 
Risk-free interest rate (%)   4.21-4.44    2.50-4.05 
Schedule of Summary of Options Granted to Purchase A summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows:
   For the Nine Months Ended
September 30, 2023		 
   Number of
Options		   Weighted
Average
Exercise Price		   Aggregate
Intrinsic
Value		 
Outstanding at the beginning of period   4,769,441   $2.93   $40 
Granted   1,625,000   $0.40      
Forfeited   (329,860)  $2.32      
Expired   (154,245)  $4.69      
Exercised   
-
   $
-
      
Outstanding at the end of period   5,910,336   $2.22   $76 
Exercisable at the end of period   3,234,658   $3.02      
Weighted average remaining contractual life of outstanding options – years as of September 30, 2023   7.03           

 
Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock As of September 30, 2023, the Company had the following outstanding compensation related warrants to purchase Common Stock:
Warrant  Issuance
Date		  Expiration
Date		   Exercise
Price
Per Share		   Number of
Shares of
Common Stock
Underlying
Warrants		 
Private Warrants issued to scientific founders (see below)  November 27, 2017   
        -
    
         -
    2,974 
Schedule of Stock-Based Payment Expenses The following table sets forth the total stock-based payment expenses resulting from options granted, included in the statements of operations:
   Three Months Ended
September 30,		   Nine Months Ended
September 30,		 
   2023   2022   2023   2022 
Research and development expenses, net   31    104    202    352 
General and administrative   164    259    439    810 
    195    363    641    1,162